A bradykinin antagonist modifies allergen-induced mediator release and late bronchial responses in sheep.
We assessed the role of bradykinin (BK) in allergen-induced early and late bronchial responses, airway inflammation, mediator release, and antigen-induced airway hyperresponsiveness in allergic sheep by studying the effects of the BK B2 receptor antagonist, NPC-567 (D-Arg-[Hyp3, D-Phe7]-BK), on these parameters. Antigen challenge was performed on two occasions greater than 3 wk apart, once with placebo (control) and once after high-dose (10 mg/ml) and low-dose (5 mg/ml) treatments with aerosol NPC-567. In the control trials (n = 14) antigen challenge resulted in an early and late increase in specific lung resistance (SRL). The early response was associated with increases (p less than 0.05) in prostaglandin (PG) D2, immunoreactive kinin, tosyl-L-arginine methyl ester (TAME)-esterase, and PGE2 in bronchoalveolar lavage (BAL) fluid. The late response was associated with increases (p less than 0.05) in leukotrienes (LT) B4 and C4, thromboxane (TX) B2, 6-keto-PGF10, and PGE2. There was a significant influx of neutrophils in the BAL fluid during the late response, and airway hyperresponsiveness to carbachol aerosol was apparent 4 h after challenge. In six sheep the high-dose NPC-567 treatment (given before, during, and 4 h after antigen challenge) did not attenuate the early bronchoconstrictor response or the early release of mediators but caused a significant reduction in the late response (p less than 0.05). This protective effect was accompanied by reductions (p less than 0.05) in both the concentrations of all the mediators associated with the late response and the severity of the BAL neutrophilia. High-dose NPC-567 did not attenuate the airway hyperresponsiveness or the cellular inflammatory response seen 24 h after challenge. In eight sheep treated with the low dose of NPC-567 (given before, during, and 4, 8, and 24 h after challenge) the early response was not blocked but the late response was again inhibited, as were the mediators associated with the late response. At the low dose the drug did not prevent the airway inflammation at 8 or 24 h. The additional treatments did, however, prevent the 24 h hyperresponsiveness. These data suggest that kinin generation during antigen-induced airway anaphylaxis may be important for controlling the release of arachidonic acid metabolites from airway inflammatory cells that contribute to the development of the late response in the allergic sheep model.
Abraham
W M
WM
Department of Research, Mount Sinai Medical Center, Miami Beach, Florida 33140.
Burch
R M
RM
Farmer
S G
SG
Sielczak
M W
MW
Ahmed
A
A
Cortes
A
A
D000403:Airway Resistance / Q000502:physiology; D000485:Allergens / Q000502:physiology*; D000818:Animals; D001920:Bradykinin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000037:antagonists & inhibitors* / Q000494:pharmacology / Q000502:physiology; D001992:Bronchoalveolar Lavage Fluid / Q000737:chemistry / Q000473:pathology; D016084:Bronchoconstriction / Q000187:drug effects / Q000502:physiology*; D007249:Inflammation / Q000503:physiopathology; D007610:Kallikreins / Q000378:metabolism; D007962:Leukocytes / Q000473:pathology; D015289:Leukotrienes / Q000378:metabolism; D010447:Peptide Hydrolases / Q000378:metabolism; D011453:Prostaglandins / Q000378:metabolism; D012130:Respiratory Hypersensitivity / Q000378:metabolism / Q000503:physiopathology*; D012756:Sheep; D013929:Thromboxane B2 / Q000378:metabolism
D000485:Allergens; D015289:Leukotrienes; D011453:Prostaglandins; D013929:Thromboxane B2; C053010:NPC 567; D010447:Peptide Hydrolases; C023073:tosylarginine methyl ester hydrolase; D007610:Kallikreins; D001920:Bradykinin